Slingshot members are tracking this event:

Allergan Receives Positive Opinion For Truberzi (Eluxadoline) For Treatment Of Irritable Bowel Syndrome With Diarrhoea (IBS-D) In Adults

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details -- TRUBERZI® first-in-class medication offering sustained relief from multiple symptoms of IBS-D, such as pain, diarrhoea, urgency and bloating(1,2) --
-- Significant step towards bringing the only licensed prescription medication for IBS-D to patients in 28 countries of the European Union(2-4) --
-- Further demonstrates Allergan's commitment to addressing unmet medical needs in gastrointestinal disease by providing innovative medicines for patients and physicians --

TRUBERZI® significantly reduced two of the most bothersome symptoms of IBS-D, abdominal pain and diarrhoea, with sustained relief demonstrated over six months1,2.  TRUBERZI® was generally well tolerated with the most common side effects being nausea, constipation, and abdominal pain1,2.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 25, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Truberzi, Eluxadoline, Irritable Bowel Syndrome, Ibs-d, Abdominal Pain, Diarrhea